Revolution Medicines began shipping daraxonrasib to physicians and patients under an FDA-authorized early access program, the company said during an event tied to ASCO. Daraxonrasib remains investigational and not yet approved, but demand accelerated after the company reported striking Phase 3 outcomes earlier in April. The early access program is designed to deliver the drug before a formal regulatory decision, and Revolution’s CEO Mark Goldsmith told STAT the company is now distributing treatment through the program as patients seek the option. The move follows Revolution’s reported trial results showing nearly doubled survival versus standard chemotherapy in the metastatic pancreatic cancer setting. For the field, early access shipment signals both clinical urgency and an expectation of strong interest from treating sites, while also intensifying operational demands for supply chain readiness as trial and real-world usage overlap.